ABL1 and plasma cell myeloma: Our current findings provide new evidence that the FDA-approved allosteric inhibitor asciminib, which also changes c-Abl conformation to expose the myristoylation site, re-localizes c-Abl to the ER, and induces global UPR regardless of its kinase activity in myeloma cell lines.